This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Time to Tap Healthcare ETFs on Nvidia's AI Ambition?
by Sanghamitra Saha
At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.
5 Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week.The optimism surrounding the likely Fed rate cuts in 2024 aided the rally in the market, barring some occasional dips.
Sector ETFs to Gain as Fed Stays Put, Sees Deeper Rate Cuts in 2024
by Sanghamitra Saha
The Federal Reserve held its benchmark interest rate steady at a range of 5.25%-5.50% on Dec 13. However, the Fed hinted at three 25-bp rate cuts next year.
Best-Performing ETFs of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week. The reason behind the market rally was cooling inflation. Softening in the inflation data triggered the possibility of a less-hawkish Fed, going forward.
The Zacks Analyst Blog Highlights ARK Innovation ETF, ARK Genomic Revolution ETF, iShares U.S. Home Construction ETF, ETFMG Alternative Harvest ETF and iShares U.S. Regional Banks ETF
by Zacks Equity Research
ARK Innovation ETF, ARK Genomic Revolution ETF, iShares U.S. Home Construction ETF, ETFMG Alternative Harvest ETF and iShares U.S. Regional Banks ETF are included in this Analyst Blog.
5 Sector ETFs at the Forefront of the Market Rally Last Week
by Sweta Killa
Wall Street wrapped up the best week of 2023 to start November driven by increased investor confidence, buoyed by solid corporate earnings and signals that the Fed's aggressive interest rate hiking campaign might be nearing an end.
5 ETF Areas That Spooked Investors in October
by Sanghamitra Saha
After a downbeat September, October too remained volatile for Wall Street due to higher rates.
Is Now the Right Time to Embrace Biotech ETFs?
by Yashwardhan Jain
Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.
4 Sectors & Their ETFs Returning Double-Digits to Start 2023
by Sanghamitra Saha
Wall Street has been showing immense strength to start 2023. These sectors and their ETFs have returned double-digit returns to start 2023.
Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was pretty upbeat last week due to cooling inflation.
A Comprehensive Guide to Genomic ETFs
by Zacks Equity Research
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Should You Buy Beaten-Down Biotech Stocks & ETFs?
by Neena Mishra
We highlight 4 ETFs that have started rebounding after a brutal sell-off
A Comprehensive Guide to Genomic ETFs
by Zacks Equity Research
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
ETFs Winners of S&P 500's Second Best Week in 2022
by Sanghamitra Saha
The S&P 500 advanced more than 3% on Friday, logging back-to-back days of gains and marking its first weekly advance since late May.
US Stocks Float Higher Ahead Of Q1 Earnings Season
by Daniel Laboe
Market undertones are turning from a mere buy-the-dip rally to demonstrating real breakout internals
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Zacks Market Edge Highlights: ARKK, ARKG, CTRU, QQQM, and XBI
by Zacks Equity Research
Zacks Market Edge Highlights: ARKK, ARKG, CTRU, QQQM, and XBI
Should You Bet on Cathie Wood in 2022?
by Tracey Ryniec
Two of ARK Invest's most popular ETFs were down double digits in 2021. Is it time to buy?
Is ARK's Stellar Run Over? 5 ETF Themes to Follow Cathie Wood
by Sanghamitra Saha
Though Cathie Wood's Ark Investment¿¿¿s star products underperformed in 2021 and may continue to lag the broader market in 2022, Wood's fans may follow these ETF strategies to capitalize on her vision.
How Did Cathie Wood's ARK Invest Perform in 2021?
by Sweta Jaiswal, FRM
Let's take a look at how ARK Invest ETFs performed in 2021.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
How Are Genomics ETFs Responding to Q2 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.